{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0000", "char_start": 0, "char_end": 1200, "pages": [1], "text": "August 2021\nVolume 37 | Number 10\nStatewide Formulary for Opioid Dependence Agents\nand Opioid Antagonists\n10/1/2021 New Information highlighted below\nEffective October 1, 2021, per the enacted New York State (NYS) Budget for State Fiscal Year (SFY) 2020-\n2021, in accordance with §367-a (7)(e) of Social Services Law, the NYS Department of Health (DOH) is\nimplementing a single statewide formulary for Opioid Antagonists and Opioid Dependence Agents for NYS\nMedicaid fee-for-service (FFS) as well as Medicaid Managed Care (MMC). Under this statewide formulary,\nNYS Medicaid FFS and MMC will:\n• follow a single formulary when:\ncoverage parameters are consistent across the Medicaid Program,\npreferred products are available without prior authorization (PA) when prescribed consistent\nwith Food and Drug Administration (FDA) package labeling, and\nnon-preferred products require PA; as well as\n• use standard clinical criteria for approval of a non-preferred drug in accordance with §273 (3)(a) of\nPublic Health Law.\nSingle Statewide Formulary – Effective October 1, 2021\nOpioid Antagonists*\nPreferred Non-Preferred Coverage Parameters\nnaloxone (syringe, vial) None Not Applicable\nnaltrexone None Not Ap", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0001", "char_start": 1200, "char_end": 1491, "pages": [1], "text": "plicable\nNARCAN® (nasal spray) None Not Applicable\nOpioid Dependence Agents - Injectable*\nPreferred Non-Preferred Coverage Parameters\nSUBLOCADE® None Not Applicable\nVIVITROL® None Not Applicable\n*All agents are subject to FDA-approved quantity/frequency/duration limits.\nContinued on Page 3\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0052::table", "char_start": null, "char_end": null, "pages": [1], "text": ",Preferred,,,Non-Preferred,,,Coverage Parameters,\r\n,\"naloxone (syringe, vial)\",,,None,,,Not Applicable,\r\n,naltrexone,,,None,,,Not Applicable,\r\nNARCAN® (nasal spray),,,None,,,Not Applicable,,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0053::table", "char_start": null, "char_end": null, "pages": [1], "text": ",Preferred,,,Non-Preferred,,,Coverage Parameters,\r\n,SUBLOCADE®,,,None,,,Not Applicable,\r\nVIVITROL®,,,None,,,Not Applicable,,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0002", "char_start": 1602, "char_end": 2802, "pages": [2], "text": "\n\nKathy Hochul\nGovernor\nState of New York\nHoward A. Zucker, M.D., J.D.\nCommissioner\nNew York State\nDepartment of Health\nBrett R. Friedman\nActing Medicaid Director\nOffice of Health Insurance Programs\nThe Medicaid Update is a monthly publication of the New York State Department of Health.\nIn This Issue…\nStatewide Formulary for Opioid Dependence Agents and Opioid Antagonists.................................................. Cover\nAll Providers\nClarification on Previous Guidance:\nNational Drug Code Usage for Physician Administered Drugs with Ambulatory Patient Groups .................................6\nMedicaid Consumer Fact Sheets Now Available ................................................................................................8\nNY State of Health: Higher Income New Yorkers May Now Qualify\nfor Financial Assistance to Lower the Cost of Health Coverage ............................................................................8\nPharmacy\nNew York State Medicaid Fee-for-Service Program: Pharmacists as Immunizers Fact Sheet....................................9\nClarification and Reminder: Pharmacy Providers Servicing\nMedicaid Fee-for-Service Members and Medicaid Managed Care Enr", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0003", "char_start": 2802, "char_end": 4002, "pages": [2, 3], "text": "ollees ........................................................ 13\nPolicy and Billing\nNew Billing Requirement for Home Health Agencies: Demand Billing, No-Pay RAP .............................................. 15\nNew York State Medicaid Drug Testing Policy ................................................................................................. 16\nNew York State Medicaid Expansion of Non-Invasive Prenatal Trisomy Screening Policy ...................................... 18\nMosquito Repellent Coverage Discontinued .................................................................................................... 20\nProvider Directory ............................................................................................................................... 21\nAugust 2021 New York State Medicaid Update pg. 2\n\nAll Providers\nOpioid Dependence Agents - Oral/Transmucosal*\nPreferred Non-Preferred Coverage Parameters\nbuprenorphine Bunavail™ Clinical Criteria (CC): PA required for initiation of opioid therapy for\nSUBOXONE® Buprenorphine/ patients on established opioid dependence therapy.\n** Naloxone film\nbuprenorphine/ ZUBSOLV® Quantity Limit (QL):\nnaloxone tablet • buprenorphine ", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0004", "char_start": 4002, "char_end": 5202, "pages": [3], "text": "sublingual (SL): Six tablets dispensed as a\ntwo-day supply; not to exceed 24 mg per day\n• buprenorphine/ naloxone tablet and film (Bunavail™,\nSUBOXONE®, ZUBSOLV® up to 5.7 mg/1.4 mg strength):\nThree sublingual tablets or films per day; maximum of 90\ntablets or films dispensed as a 30-day supply; not to exceed 24\nmg-6 mg of SUBOXONE®, or its equivalent per day\n• buprenorphine/naloxone tablet (ZUBSOLV® 8.6 mg/2.1 mg\nstrength): Maximum of 60 tablets dispensed as a 30-day\nsupply\n• buprenorphine/naloxone tablet (ZUBSOLV® 11.4 mg/2.9\nmg strength): Maximum of 30 tablets dispensed as a 30-day\nsupply\n*All agents are subject to FDA-approved quantity/frequency/duration limits.\n**A new prescription is not required when a member is switching from the generic product to the brand product, consistent with the\nMedicaid FFS Brand Less Than Generic (BLTG) program, which can be found on the Magellan Health Inc. “BLTG program” web page\nat: https://newyork.fhsc.com/providers/BLTGP_about.asp. The prescription will have a generic copayment and does not require\n“Dispense as Written (DAW)” or “Brand Medically Necessary” on the prescription. This applies to SUBOXONE®, only.\nMMC Billing\n• MMC enrollees will ", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0005", "char_start": 5202, "char_end": 6402, "pages": [3, 4], "text": "continue to access these medications by presenting their plan card to the\npharmacy.\n• PA is required for all non-preferred agents. Providers should contact the MMC plan to obtain\nauthorization when necessary. Contact and billing information can be found on the NYS “MMC\nPharmacy Benefit Information Center” web page at: https://mmcdruginformation.nysdoh.suny.edu/.\n• MMC Plans will notify pharmacy providers about using the brand product SUBOXONE® instead of the\ngeneric alternative, consistent with Medicaid FFS:\nMMC Plans will provide guidance on DAW Code requirements.\nMMC Plans will reimburse claims consistent with brand drug reimbursement for SUBOXONE®.\nIf a pharmacy is out of stock of brand name SUBOXONE® and the member needs the\nmedication, the pharmacist should contact the MMC Plan for a one-time override to allow for\nthe generic equivalent to be dispensed until the brand is restocked.\nAugust 2021 New York State Medicaid Update pg. 3\n\nMedicaid FFS Billing\n• Medicaid FFS members will continue to access these medications by presenting their Medicaid benefit\ncard to the pharmacy.\n• PA is required for all non-preferred agents. Providers should contact Magellan plan to obtain\nauthoriza", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0054::table", "char_start": null, "char_end": null, "pages": [3], "text": ",Preferred,,,Non-Preferred,,,Coverage Parameters,\r\n,buprenorphine,,,Bunavail™,,,Clinical Criteria (CC): PA required for initiation of opioid therapy for,\r\n,SUBOXONE®,,,Buprenorphine/,,,patients on established opioid dependence therapy.,\r\n,**,,,Naloxone film,,,,\r\n\"buprenorphine/\nnaloxone tablet\",,,ZUBSOLV®,,,,Quantity Limit (QL):,\r\n,,,,,,,• buprenorphine sublingual (SL): Six tablets dispensed as a,\r\n,,,,,,,two-day supply; not to exceed 24 mg per day,\r\n,,,,,,,\"• buprenorphine/ naloxone tablet and film (Bunavail™,\",\r\n,,,,,,,\"SUBOXONE®, ZUBSOLV® up to 5.7 mg/1.4 mg strength):\",\r\n,,,,,,,Three sublingual tablets or films per day; maximum of 90,\r\n,,,,,,,tablets or films dispensed as a 30-day supply; not to exceed 24,\r\n,,,,,,,\"mg-6 mg of SUBOXONE®, or its equivalent per day\",\r\n,,,,,,,• buprenorphine/naloxone tablet (ZUBSOLV® 8.6 mg/2.1 mg,\r\n,,,,,,,strength): Maximum of 60 tablets dispensed as a 30-day,\r\n,,,,,,,supply,\r\n,,,,,,,• buprenorphine/naloxone tablet (ZUBSOLV® 11.4 mg/2.9,\r\n,,,,,,,mg strength): Maximum of 30 tablets dispensed as a 30-day,\r\n,,,,,,,supply,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0055::table", "char_start": null, "char_end": null, "pages": [3], "text": "\"If a pharmacy is out of stock of brand name SUBOXONE® and the member needs the\no\",\r\n,\"medication, the pharmacist should contact the MMC Plan for a one-time override to allow for\"\r\n,the generic equivalent to be dispensed until the brand is restocked.\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0006", "char_start": 6402, "char_end": 7602, "pages": [4], "text": "tion when necessary. Contact and billing information can be found on the Magellan Health\nInc. “NYS Medicaid Pharmacy Programs” home page at: https://newyork.fhsc.com/.\n• Pursuant to the Medicaid FFS BLTG program for prescription claims submitted, Medicaid FFS:\nmessages pharmacy providers about utilizing the brand product SUBOXONE® instead of the\ngeneric alternative; and\nreimburses claims consistent with Medicaid FFS-approved drug reimbursement for brand\nname drugs.\nPharmacies will receive the following National Council for Prescription Drug Programs (NCPDP)\nImplementation messages for the Product/Service ID, field 407-D7, when a generic National Drug Code\n(NDC) is submitted:\nCode Type Code Message Field Resources\nNCPDP Reject “78”* Cost Exceeds FIELD 511-FB NCPDP\nCode Maximum REJECT CODE Companion Guide:\nhttps://www.emedn\ny.org/HIPAA/5010\n/transactions/NCP\nDP_D.0_Compani\non_Guide.pdf\nNCPDP Response “421”** Dispense Brand FIELD 526-FQ eMedNY\nCode/Message Drug Instead of ADDITIONAL ProDUR/ECCA\nGeneric Equivalent MESSAGE Provider Manual\nINFORMATION: (D.0):\nInsert MEVS https://www.emedn\nResponse Code y.org/ProviderMan\nuals/Pharmacy/Pro\nDUR-D.0-\nECCA_Provider_M\nanual/Pro DUR\nECCA Provid", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0007", "char_start": 7602, "char_end": 8802, "pages": [4, 5], "text": "er\nManual (D.0).pdf\n*NYS DOH is exploring the use of the updated NCPDP Reject Code “606”: ‘Brand drug/specific labeler code required’. NYS DOH\nwill provide updated billing guidance if/when use of that NCPDP Reject Code becomes available in FFS.\n**For the Medicaid Eligibility Verification System (MEVS) Response Code, providers can visit the NYS DOH eMedNY Prospective\nDrug Utilization Review/Electronic Claims Capture and Adjudication ProDUR/ECCA Provider Manual (D.0) at:\nhttps://www.emedny.org/ProviderManuals/Pharmacy/ProDUR-D.0-ECCA_Provider_Manual/Pro DUR ECCA Provider Manual\n(D.0).pdf.\nPharmacies are not required to submit Dispense as Written (DAW)/Product Selection Code of “1”, but are\nrequired to submit DAW Code of “9” in field 408-D8:\nCode Type Code Code Description Field\nDAW Code “9” Substitution allowed by Prescriber – 408-D8\nPlan Request Brand\nPharmacies will receive the following NCPDP message when the appropriate DAW code is not submitted in\nfield 408-D8:\nCode Type Code Message Field\nNCPDP Reject Code “22” M/I Dispense as Written Code 408-D8\nAugust 2021 New York State Medicaid Update pg. 4\n\nQuestions and Additional Information:\n• The Single Statewide Medication Assisted Tr", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0056::table", "char_start": null, "char_end": null, "pages": [4], "text": ",Code Type,,,Code,,,Message,,,Field,,,Resources,\r\n\"NCPDP Reject\nCode\",,,“78”*,,,\"Cost Exceeds\nMaximum\",,,\"FIELD 511-FB\nREJECT CODE\",,,\"NCPDP\nCompanion Guide:\nhttps://www.emedn\ny.org/HIPAA/5010\n/transactions/NCP\nDP_D.0_Compani\non_Guide.pdf\",,\r\n\"NCPDP Response\nCode/Message\",,,“421”**,,,\"Dispense Brand\nDrug Instead of\nGeneric Equivalent\",,,\"FIELD 526-FQ\nADDITIONAL\nMESSAGE\nINFORMATION:\nInsert MEVS\nResponse Code\",,,\"eMedNY\nProDUR/ECCA\nProvider Manual\n(D.0):\nhttps://www.emedn\ny.org/ProviderMan\nuals/Pharmacy/Pro\nDUR-D.0-\nECCA_Provider_M\nanual/Pro DUR\nECCA Provider\nManual (D.0).pdf\",,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0057::table", "char_start": null, "char_end": null, "pages": [4], "text": ",Code Type,,,Code,,,Code Description,,,Field,\r\nDAW Code,,,“9”,,,\"Substitution allowed by Prescriber –\nPlan Request Brand\",,,408-D8,,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0058::table", "char_start": null, "char_end": null, "pages": [4], "text": ",Code Type,,,Code,,,Message,,,Field,\r\nNCPDP Reject Code,,,“22”,,,M/I Dispense as Written Code,,,408-D8,,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0008", "char_start": 8802, "char_end": 9848, "pages": [5], "text": "eatment (MAT) Formulary web site can be found at:\nhttps://newyork.fhsc.com/providers/mat.asp.\n• The All Stakeholder: Implementation Update Statewide Formulary for Opioid Dependence Agents and\nOpioid Antagonists webinar regarding Single Statewide MAT can be found at:\nhttps://health.ny.gov/health_care/medicaid/redesign/mrt2/meetings/docs/2021-08-31_mtg1.pdf.\n• MMC billing and/or PA requirement questions should be referred to the NYS “MMC Pharmacy Benefit\nInformation Center” web page at: https://mmcdruginformation.nysdoh.suny.edu/.\n• Medicaid FFS billing/claims questions should be directed to General Dynamics Information\nTechnology Company (GDIT) at (800) 343-9000.\n• Medicaid FFS PA requirement questions should be directed to Magellan Health Inc. at (877) 309-\n9493.\n• Medicaid FFS policy questions should be directed to the Medicaid Pharmacy Policy Unit at\nppno@health.ny.gov.\n• Medicaid FFS BLTG program information can be found on the Magellan Health Inc. “BLTG program”\nweb page at: https://newyork.fhsc.com/providers/BLTGP_about.asp.\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0009", "char_start": 9959, "char_end": 11159, "pages": [5, 6], "text": "\nAugust 2021 New York State Medicaid Update pg. 5\n\nClarification on Previous Guidance:\nNational Drug Code Usage for Physician Administered Drugs\nwith Ambulatory Patient Groups\nPrevious guidance regarding the Ambulatory Patient Group (APG) fee schedule and APG Group, states that\nan accurate National Drug Code (NDC) must be reported for all physician-administered drugs billed to\nMedicaid fee-for-service (FFS) on an institutional claim that uses APGs. This Medicaid Update article clarifies\nutilizing multiple NDCs for the same drug on the same date of service and does not affect previous guidance.\nThe previous April 2019 Medicaid Update guidance titled, Reporting of the National Drug Code is Required\nfor all Fee-for-Service Physician Administered Drugs, found at:\nhttps://www.health.ny.gov/health_care/medicaid/program/update/2019/apr19_mu.pdf, required providers to\nreport accurate NDCs for all FFS, physician-administered drugs.\nBilling Drugs from the APG Group\nProviders should not bill multiple claim lines with the same physician administered drugs (commonly referred\nto as J-code drugs) on the same date of service, even if the drugs administered have different NDCs. If a\nprovider bills ", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0010", "char_start": 11159, "char_end": 12359, "pages": [6], "text": "in this manner and the drug is assigned to a single APG group, the provider will be overpaid;\nboth claim lines will pay in full. To avoid this overpayment, providers should combine all units of the J-code\ndrug administered and bill it on one claim line with the NDC reported for the claim that has the highest number\nof units administered. If the same number of units were administered for each NDC/J code, providers should\nchoose one NDC to use for submitted claims. If claims have been submitted with multiple lines for a single J-\ncode drug that paid through the APG Group, these claims were overpaid. Providers are required to adjust\ntheir claims and bill the drugs administered on one claim line (retroactive to July 1, 2019).\nExample 1:\nThe following is an example of what not to do for a drug claim from an APG Group:\nLine Proc Code Procedure Code Mod 1 Mod 2 Units of NDC Expected APG Description Payment Allowed Add-on Full APG Total\nDescription Service APG Action Weight Payment Payment Payment\n1 99212 Office/outpatient None None -- None 871 SIGNS, SYMPTIONS Full 0.6968 $ -- $127.88 $127.88\nvisit est AND OTHER FACTORS Payment\nINFLUENCING\nHEALTH STATUS\n2 J0180 agalsidase beta UD None 35 ", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0011", "char_start": 12359, "char_end": 13559, "pages": [6], "text": "58468-0040- 464 CLASS XII COMBINED Full 50.0061 $25.42 $6,000.73 $6,026.15\ninj 01 CHEMOTHERAPY AND Payment\nPHARMACOTHERAPY\n3 J0180 agalsidase beta UD None 29 58469-0041- 464 CLASS XII COMBINED Full 50.0061 $ -- $6,000.73 $6,000.73\ninj 01 CHEMOTHERAPY AND Payment\nPHARMACOTHERAPY\n4 J0180 agalsidase beta UD JW 1 58468-0041- 464 CLASS XII COMBINED No 0.0000 $ -- $ -- $ --\ninj 01 CHEMOTHERAPY AND Payment\nPHARMACOTHERAPY\nExample 2:\nThe following is an example of how to properly bill the above claim for a drug from an APG Group:\nLine Proc Code Procedure Code Mod 1 Mod 2 Units NDC Expected APG Description Payment Allowed Add-on Full APG Total\nDescription of APG Action Weight Payment Payment Payment\nServi\nce\n1 99212 Office/ None None -- None 871 SIGNS, SYMPTIONS Full 0.6968 $ -- $127.88 $127.88\noutpatient visit AND OTHER FACTORS Payment\nest INFLUENCING\nHEALTH STATUS\n2 J0180 agalsidase beta UD None 64 58468-0040-01 464 CLASS XII COMBINED Full 50.0061 $25.42 $6,000.73 $6,026.15\ninj CHEMOTHERAPY AND Payment\nPHARMACOTHERAPY\n3 J0180 agalsidase beta UD JW 1 58469-0041-01 464 CLASS XII COMBINED No 0.0000 $ -- $ -- $ --\ninj CHEMOTHERAPY AND Payment\nPHARMACOTHERAPY\nTotal Paid $6,154.03\nAbbreviations", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0012", "char_start": 13559, "char_end": 14759, "pages": [6, 7], "text": ": \"est\" - established patient; \"inj\" - Injection; \"Mod\" - Modifier; \"Proc\" - Procedure\nModifier Codes: \"JW\" - used to report the drug amount discarded, or not administered, by the patient. This modifier should only be\nappended to drugs or biologicals that are single-dose vials or packages; \"UD\" - required to identify a 340B purchased drug in addition\nto the corresponding HCPCS system and NDC\nAugust 2021 New York State Medicaid Update pg. 6\n\nIn Example 2, the third from Example 1 is removed and all units provided to the patient are added to Line 2.\nThe first NDC was chosen as it reflects the drug with the most units provided while the drug waste logic did\nnot change. For guidance on drug waste logic, providers can refer to the Clarification of Policy for Practitioner,\nOrdered Ambulatory, and APG Reimbursement - and - New Billing Instructions for Wasted Drugs Using\nModifier JW article within the August 2015 issue of the Medicaid Update at:\nhttps://www.health.ny.gov/health_care/medicaid/program/update/2015/august15_mu.pdf.\nBilling Drugs from the APG Fee Schedule\nProviders may continue to code multiple lines to denote different NDCs when billing only for physician-\nadministered drugs t", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0059::table", "char_start": null, "char_end": null, "pages": [6], "text": "Line,Proc Code,Procedure Code,,,Mod 1,Mod 2,,Units of,NDC,Expected,,APG Description,,,,Payment,Allowed,,Add-on,Full APG,Total\r\n,,Description,,,,,,Service,,APG,,,,,,Action,Weight,,Payment,Payment,Payment\r\n1,99212,\"Office/outpatient\nvisit est\",,,None,None,,--,None,871,,\"SIGNS, SYMPTIONS\nAND OTHER FACTORS\nINFLUENCING\nHEALTH STATUS\",,,,\"Full\nPayment\",0.6968,,$ --,$127.88,$127.88\r\n,,,,,,,,,,,,,,TUS,,,,,,,\r\n2,J0180,\"agalsidase\ninj\",be,ta,UD,No,ne,35,\"58468-0040-\n01\",46,4,\"CL\nCH\nPH\",\"ASS XII COM\nEMOTHERA\nARMACOTH\",\"BINED\nPY AND\nERAPY\",NED,\"Full\nPayment\",50.00,61,$25.42,\"$6,000.73\",\"$6,026.15\"\r\n,,,,,,,,,,,,,,,APY,,,,,,\r\n3,J0180,\"agalsidase beta\ninj\",,,UD,None,,29,\"58469-0041-\n01\",464,,\"CLASS XII COMBINED\nCHEMOTHERAPY AND\nPHARMACOTHERAPY\",,\"BINED\nPY AND\",NED,\"Full\nPayment\",50.0061,,$ --,\"$6,000.73\",\"$6,000.73\"\r\n4,J0180,\"agalsidase beta\ninj\",,,UD,JW,,1,\"58468-0041-\n01\",464,,\"CLASS XII COMBINED\nCHEMOTHERAPY AND\nPHARMACOTHERAPY\",,,,\"No\nPayment\",0.0000,,$ --,$ --,$ --\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0060::table", "char_start": null, "char_end": null, "pages": [6], "text": "Line,Proc Code,Procedure Code,Mod 1,,Mod 2,Units,NDC,,Expected,,APG Description,,Payment,,,Allowed,Add-on,Full APG,Total\r\n,,Description,,,,of,,,APG,,,,Action,,,Weight,Payment,Payment,Payment\r\n,,,,,,Servi,,,,,,,,,,,,,\r\n,,,,,,ce,,,,,,,,,,,,,\r\n1,99212,\"Office/\noutpatient visit\nest\",None,None,,--,None,,871,,\"SIGNS, SYMPTIONS\nAND OTHER FACTORS\nINFLUENCING\nHEALTH STATUS\",,\"Full\nPayment\",,,0.6968,$ --,$127.88,$127.88\r\n,,,,,,,,,,,,,,,,,,,\r\n2,J0180,\"agalsidase beta\ninj\",UD,None,,64,58468-004,0-01,464,,\"CLAS\nCHEM\nPHAR\",\"S XII COMBINED\nOTHERAPY AND\nMACOTHERAPY\",\"Full\nPaym\",ent,,50.0061,$25.42,\"$6,000.73\",\"$6,026.15\"\r\n3,J0180,\"agalsidase beta\ninj\",UD,JW,,1,58469-0041-01,,464,,\"CLASS XII COMBINED\nCHEMOTHERAPY AND\nPHARMACOTHERAPY\",,\"No\nPayment\",,,0.0000,$ --,$ --,$ --\r\nTotal Paid,,,,,,,,,,,,,,,,,,,\"$6,154.03\"\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0013", "char_start": 14759, "char_end": 15345, "pages": [7], "text": "hrough the APG Fee Schedule. Providers can refer to the NYS DOH “APG and Px-Based\nWeights History and APG Fee Schedules” web page at:\nhttps://www.health.ny.gov/health_care/medicaid/rates/methodology/history_and_fee_schedule.htm.\nQuestions:\n• All Medicaid FFS coverage and policy questions should be directed to the Office of Health Insurance\nPrograms (OHIP) Division of Program Development and Management (DPDM) by phone at\n(518) 473−2160 or by email at FFSMedicaidPolicy@health.ny.gov.\n• All FFS billing/claims questions should be directed to the eMedNY Call Center at (800) 343-9000.\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0014", "char_start": 15455, "char_end": 16532, "pages": [7, 8], "text": "\nAugust 2021 New York State Medicaid Update pg. 7\n\nMedicaid Consumer Fact Sheets Now Available\nFollowing a recommendation from the Medicaid Redesign Team (MRT) II, the New York State (NYS)\nDepartment of Health (DOH) Office of Health Insurance Programs (OHIP) created Medicaid consumer fact\nsheets focused on chronic health conditions. Each fact sheet provides information regarding how a condition\ncan be prevented or managed, as well as relevant Medicaid benefits that can be used to help members stay\nhealthy. Topics include sickle cell disease, diabetes, high blood pressure, asthma control, HIV-PrEP (Human\nImmunodeficiency Virus - Pre-Exposure Prophylaxis), and smoking cessation. Fact sheets can be found on\nthe MRT II Policies and Guidance web page, at: https://health.ny.gov/health_care/medicaid/\nredesign/mrt2/policy/index.htm, and are available in English, Spanish, Traditional Chinese, Russian, Haitian\nCreole, Bengali, and Korean. The most recently added Sickle Cell Disease fact sheet is also available in\nSimplified Chinese, Polish, Yiddish, Arabic, and Italian.\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0015", "char_start": 16643, "char_end": 17843, "pages": [8], "text": "\nNY State of Health: Higher Income New Yorkers May Now Qualify\nfor Financial Assistance to Lower the Cost of Health Coverage\nNew federal financial assistance is now available through NY State of Health to qualifying, higher-income\nindividuals. This financial assistance is being implemented as part of the American Rescue Plan Act (ARPA)\nsigned into law on March 11, 2021, which can be found at: https://www.congress.gov/bill/117th-\ncongress/house-bill/1319/text.\nNearly 120,000 enrollees with income below 400 percent federal poverty level (FPL) are already receiving\nenhanced tax credits and nearly 18,000 higher-income enrollees are eligible for these federal tax credits for\nthe first time. Higher-income individuals enrolled outside of NY State of Health and uninsured individuals may\nalso be eligible for enhanced tax credits available through NY State of Health. Before the ARPA, tax credits\nwere not available to higher-income individuals and their families (i.e., those earning more than $51,040 and\nfamilies of four earning more than $104,800). Through the ARPA, these federal tax credits are available to\nthese individuals and their families when enrolling in a health plan through NY Stat", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0016", "char_start": 17843, "char_end": 19043, "pages": [8], "text": "e of Health.\nIndividuals with low and moderate incomes (i.e., those earning up to $51,040 and families of four earning up\nto $104,800) who were previously eligible for tax credits are now eligible for higher tax credits. NY State of\nHealth automatically applied higher tax credits without enrollees needing to take any action. Enrollees can\nmake changes to their account by logging into their NY State of Health account, contacting an Enrollment\nAssistor, and/or calling NY State of Health at (855) 355-5777.\nTo allow as many individuals as possible to access these enhanced tax credits, the 2021 Open Enrollment\nPeriod has been extended through December 31, 2021. Individuals and families can apply for coverage\nthrough the NY State of Health website at: http://www.nystateofhealth.ny.gov, by phone at (855) 355-5777,\nor by connecting with a free enrollment assistor via the NY State of Health Find a Broker/Navigator” search\ntool at: https://nystateofhealth.ny.gov/agent/hx_brokerSearch?fromPage=INDIVIDUAL&lang=en.\nAdditional Information\nTo read more about how NY State of Health enrollees’ benefit from the ARPA, providers can visit the How\nNY State of Health Enrollees Benefit from the American ", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0017", "char_start": 19043, "char_end": 19131, "pages": [8], "text": "Rescue Plan web page, found at:\nhttps://info.nystateofhealth.ny.gov/americanrescueplan.\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0018", "char_start": 19242, "char_end": 20442, "pages": [8, 9], "text": "\nAugust 2021 New York State Medicaid Update pg. 8\n\nPharmacy\nNew York State Medicaid Fee-for-Service Program:\nPharmacists as Immunizers Fact Sheet\nIn accordance with New York State (NYS) Education Law, pharmacists are authorized to administer the\nfollowing vaccines to patients 18 years of age and older: zoster, pneumococcal, meningococcal, tetanus,\ndiphtheria, and pertussis vaccines. For patients two years of age and older, pharmacies may administer\ninfluenza vaccines. Additional information can be found on the NYS Education Department “Administration of\nImmunizations” web page at: http://www.op.nysed.gov/prof/pharm/pharmimmunizations.htm.\nOnly Medicaid enrolled pharmacies will receive reimbursement for immunization services and products.\nServices must be provided and documented in accordance with NYS Education laws and regulations,\nincluding the reporting of all immunizations administered to members less than 19 years of age to either the\nNYS Department of Health (DOH), using the NY State Immunization Information System (NYSIIS), or to the\nNew York City Department of Health and Mental Hygiene (NYC DOHMH) using the New York Citywide\nImmunization Registry (CIR).\nPharmacies will only ", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0019", "char_start": 20442, "char_end": 21642, "pages": [9], "text": "be able to bill for Medicaid non-dual eligible members. Dual eligible members will\ncontinue to access immunization services through Medicare. Medicaid Managed Care (MMC) enrollees will\ncontinue to access immunization services through their health plans. For Medicaid Managed Care\nOrganization (MCO) billing guidance, providers must contact the individual plan. Providers can access\nindividual plan information via the NYS MMC Pharmacy Benefit Information Center web page at:\nhttps://mmcdruginformation.nysdoh.suny.edu/, then select the individual plan and choose “Pharmacy\nVaccine Billing Guidance”.\nReimbursement for these vaccines may be based on a patient specific, or non-patient specific, order. These\norders must be kept on file at the pharmacy. The ordering prescriber must be actively enrolled as a NYS\nMedicaid provider, unless otherwise exempt, and the prescribers National Provider Identifier (NPI) is required\non the claim for the claim to be paid.\nVaccines for administration to individuals under the age of 19 are recommended by the Advisory Committee\non Immunization Practices (ACIP) and are provided to Medicaid FFS members and MMC enrollees free of\ncharge by the Vaccines for Childre", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0020", "char_start": 21642, "char_end": 22842, "pages": [9], "text": "n (VFC) program.\n• Pharmacies wishing to administer VFC-available vaccines to Medicaid members under 19 years of\nage may enroll in the VFC program. Please note: The VFC program is currently enrolling\npharmacies to receive the influenza vaccine only.\n• Pharmacies enrolled in the VFC program may submit claims to FFS and MMC for the administration\nfee for VFC-eligible vaccinations administered at the pharmacy.\n• Pharmacies that are not enrolled in the VFC program may choose to provide vaccines for members\nunder 19 years of age at no charge to the member/enrollee or Medicaid program, and be reimbursed\nan immunization fee of $17.85 by NYS Medicaid.\n• Pharmacies immunizing Medicaid members 18 years of age with pneumococcal, meningococcal,\ntetanus, diphtheria, and pertussis vaccines may not bill Medicaid for the costs of these vaccines, as\nthese members are VFC-eligible such that they may receive these vaccines through a VFC healthcare\npractice or clinic.\n• NYS Medicaid should never be billed for the cost of any vaccine for persons under 19 years of age\nwhen it is available through the VFC Program. This applies to both FFS and MMC. Pharmacies that\nbill Medicaid for the cost of vaccines wh", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0021", "char_start": 22842, "char_end": 24042, "pages": [9, 10], "text": "en it is available through the VFC Program are subject to\nrecovery of payment.\nAugust 2021 New York State Medicaid Update pg. 9\n\nAdditional information on the VFC Program, based on location, can be found at the following web pages:\n• New York City (NYC): NYC Health “VFC Provider Requirements - Enrollment and Re-Certification”\nweb page (https://www1.nyc.gov/site/doh/providers/nyc-med-cir/vaccines-for-children-\nrequirements.page)\n• Outside of NYC: NYS DOH “New York State Vaccines for Children (VFC) Program” web page\n(https://www.health.ny.gov/prevention/immunization/vaccines_for_children/)\nBilling Instructions for Medicaid FFS\nConsistent with Medicaid immunization policy, pharmacies may bill the vaccine administration fee and, when\napplicable, acquisition cost of the vaccine using the appropriate procedure codes. To view a list of procedure\ncodes, providers can refer to the NYS Medicaid Pharmacy Services Fee Schedule at:\nhttps://www.emedny.org/ProviderManuals/Pharmacy/PDFS/Pharmacy_Fee_Schedule.xls.\nPlease note: National Drug Codes (NDCs) are not to be used for billing the vaccine product through\nMedicaid FFS. Reimbursement for the cost of the vaccine for members 19 years of age and ", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0022", "char_start": 24042, "char_end": 25242, "pages": [10], "text": "older will be\nmade at no more than the actual acquisition cost to the pharmacy. No dispensing fee or member co-payment\napplies. Pharmacies will bill with a quantity of “1” and a daily supply of “1”.\nTable A: Vaccine claims submitted via the National Council for Prescription Drug Programs\n(NCPDP) D.0 format\nNCPDP D.0. Claim Segment Field Value\n436-E1 (Product/Service ID Qualifier) Enter value of \"09\" which qualifies the code\nsubmitted in field 407-D7 (Product/Service ID) as a\nprocedure code.\n407-D7 (Product/Service ID) Enter an applicable procedure code listed in Table B\nand/or C. Up to four claim lines can be submitted\nwith one transaction.\n442-E7 (Quantity Dispensed) Enter the value of “1” for the procedure\nadministration code in Table B.\n405-D5 (Day Supply) Enter the value of “1”.\n411-DB (Prescriber ID) Enter Prescriber National Provider Number (NPI)\nnumber.\n454-EK (Scheduled Prescription ID Number) Enter serial number “99999999” when applicable\nfor non-patient specific orders.*\n419-DJ (Prescription Origin Code) Enter origin code “5”.*\n*For further guidance on origin code and serial number values that must be submitted on the claim, refer to the Matching Origin Codes\nto Correct P", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0023", "char_start": 25242, "char_end": 26442, "pages": [10, 11], "text": "rescription Serial Number Within Medicaid Fee-For-Service (FFS) article in the July 2016 issue of the Medicaid Update\nat: https://www.health.ny.gov/health_care/medicaid/program/update/2016/jul16_mu.pdf. For the origin code, “5” and the\ncorresponding serial number of “99999999” for “Pharmacy dispensing” is to be used for applicable non-patient specific orders.\nThe NCPDP D.0 Companion Guide can be found on the eMedNY “5010/D.0 Transaction Instructions” web page at:\nhttps://www.emedny.org/HIPAA/5010/transactions/index.aspx.\nBilling for Immunizations of Members 19 Years of Age and Older\nFor billing of administration of multiple vaccines on the same date to members 19 years of age and older,\nprocedure code “90471” should be used for the first vaccine and “90472” for any other vaccines administered\non that day. One line should be billed for “90472” indicating the additional number of vaccines administered\n(insert quantity of one or two).\nAugust 2021 New York State Medicaid Update pg. 10\n\nBilling for Immunizations of Members 19 Years of Age and Younger\nFor VFC-eligible vaccines, regardless of enrollment in the VFC Program, the pharmacy would submit\nprocedure code “90460” (administration o", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0061::table", "char_start": null, "char_end": null, "pages": [10], "text": ",NCPDP D.0. Claim Segment Field,,,Value,\r\n436-E1 (Product/Service ID Qualifier),,,\"Enter value of \"\"09\"\" which qualifies the code\nsubmitted in field 407-D7 (Product/Service ID) as a\nprocedure code.\",,\r\n407-D7 (Product/Service ID),,,\"Enter an applicable procedure code listed in Table B\nand/or C. Up to four claim lines can be submitted\nwith one transaction.\",,\r\n442-E7 (Quantity Dispensed),,,\"Enter the value of “1” for the procedure\nadministration code in Table B.\",,\r\n405-D5 (Day Supply),,,Enter the value of “1”.,,\r\n411-DB (Prescriber ID),,,\"Enter Prescriber National Provider Number (NPI)\nnumber.\",,\r\n454-EK (Scheduled Prescription ID Number),,,\"Enter serial number “99999999” when applicable\nfor non-patient specific orders.*\",,\r\n419-DJ (Prescription Origin Code),,,Enter origin code “5”.*,,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0024", "char_start": 26442, "char_end": 27642, "pages": [11], "text": "f free vaccine) for administration of first or subsequent dose and\nthen submit the appropriate vaccine procedure code(s) with a cost of $0.00. A system edit will ensure that\nwhen there is an incoming claim for the administrative fee (procedure code “90460”) there is also a claim in\nhistory for a VFC- eligible vaccine procedure code reimbursed at $0.00. If no history claim is found, the claim\nwill be denied for edit “02291”. For NCPDP claim transactions that are denied for edit “02291”, the\ncorresponding Medicaid Eligibility Verification System (MEVS) Denial Reason Code “738” History Not Found\nfor Administrative Vaccine Claim will be returned as well as the NCPDP Reject code “85”, Claim Not\nProcessed.\nTable B: The following procedure codes below should be billed for select influenza vaccines for ages\ntwo years of age and over; pneumococcal and meningococcal vaccines for 18 years of age and over;\nand zoster for 50 years of age and over.\nProcedure Code Procedure Description\n“90620” Meningococcal recombinant protein and outer membrane vesicle vaccine,\nSerogroup B, 2 dose schedule, for intramuscular use\n“90621” Meningococcal recombinant lipoprotein vaccine, Serogroup B, 2 or 3 dose sche", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0025", "char_start": 27642, "char_end": 28842, "pages": [11], "text": "dule,\nfor intramuscular use\n“90653” Influenza virus vaccine (IIV), preservative free, for use in individuals 65 years of age\nand above, for intramuscular use\n“90662” Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity\nvia increased antigen content, for intramuscular use\n“90670” Pneumococcal conjugate vaccine, 13-valent, for intramuscular use\n“90672” Influenza virus vaccine, quadrivalent, live, for intranasal use in individuals two years\nof age through 49\n“90674” Influenza virus vaccine; quadrivalent, derived from cell cultures, subunit, preservative\nand antibiotic free, for intramuscular use\n“90682” Influenza virus vaccine, quadrivalent, quadrivalent recombinant influenza vaccine\n(RIV4), derived from recombinant deoxyribonucleic acid (DNA), preservative and\nantibiotic free for intramuscular use\n“90686” Influenza virus vaccine, quadrivalent, split virus, preservative free, when\nadministered to individuals three years of age and older, for intramuscular use\n“90688” Influenza virus vaccine, quadrivalent, split virus, when administered to individuals\nthree years of age and older, with preservative, for intramuscular use\n“90694” Influenza virus vaccine", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0026", "char_start": 28842, "char_end": 30042, "pages": [11, 12], "text": ", quadrivalent (aIIV4), inactivated, adjuvanted, for individuals\n65 years of age and above, preservative free, for intramuscular use\n“90714” Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, for use in\nindividuals seven years or older, for intramuscular use\n“90715” Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), for use in\nindividuals seven years or older, for intramuscular use\n“90732” Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed\npatient dosage, for use in individuals two years of age or older, for subcutaneous or\nintramuscular use\n“90733” Meningococcal polysaccharide vaccine [any group(s)], for subcutaneous use, age\ntwo years of age and older\n“90734” Meningococcal conjugate vaccine, Serogroups A, C, Y and W-135 (trivalent), for\nintramuscular use, age 11 through 55\n“90750” Zoster (shingles) Vaccine, age 50 and older for intramuscular use\n“90756” Influenza virus vaccine, quadrivalent, antibiotic free, for intramuscular use\nAugust 2021 New York State Medicaid Update pg. 11\n\nTable C: The following procedure codes below should be used for the actual administration of the\nvaccines listed above by a pharmacist.\nProcedure Cod", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0062::table", "char_start": null, "char_end": null, "pages": [11], "text": ",Procedure Code,,,Procedure Description,\r\n“90620”,,,\"Meningococcal recombinant protein and outer membrane vesicle vaccine,\nSerogroup B, 2 dose schedule, for intramuscular use\",,\r\n“90621”,,,\"Meningococcal recombinant lipoprotein vaccine, Serogroup B, 2 or 3 dose schedule,\nfor intramuscular use\",,\r\n“90653”,,,\"Influenza virus vaccine (IIV), preservative free, for use in individuals 65 years of age\nand above, for intramuscular use\",,\r\n“90662”,,,\"Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity\nvia increased antigen content, for intramuscular use\",,\r\n“90670”,,,\"Pneumococcal conjugate vaccine, 13-valent, for intramuscular use\",,\r\n“90672”,,,\"Influenza virus vaccine, quadrivalent, live, for intranasal use in individuals two years\nof age through 49\",,\r\n“90674”,,,\"Influenza virus vaccine; quadrivalent, derived from cell cultures, subunit, preservative\nand antibiotic free, for intramuscular use\",,\r\n“90682”,,,\"Influenza virus vaccine, quadrivalent, quadrivalent recombinant influenza vaccine\n(RIV4), derived from recombinant deoxyribonucleic acid (DNA), preservative and\nantibiotic free for intramuscular use\",,\r\n“90686”,,,\"Influenza virus vaccine, quadrivalent, split virus, preservative free, when\nadministered to individuals three years of age and older, for intramuscular use\",,\r\n“90688”,,,\"Influenza virus vaccine, quadrivalent, split virus, when administered to individuals\nthree years of age and older, with preservative, for intramuscular use\",,\r\n“90694”,,,\"Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, for individuals\n65 years of age and above, preservative free, for intramuscular use\",,\r\n“90714”,,,\"Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, for use in\nindividuals seven years or older, for intramuscular use\",,\r\n“90715”,,,\"Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), for use in\nindividuals seven years or older, for intramuscular use\",,\r\n“90732”,,,\"Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed\npatient dosage, for use in individuals two years of age or older, for subcutaneous or\nintramuscular use\",,\r\n“90733”,,,\"Meningococcal polysaccharide vaccine [any group(s)], for subcutaneous use, age\ntwo years of age and older\",,\r\n“90734”,,,\"Meningococcal conjugate vaccine, Serogroups A, C, Y and W-135 (trivalent), for\nintramuscular use, age 11 through 55\",,\r\n“90750”,,,\"Zoster (shingles) Vaccine, age 50 and older for intramuscular use\",,\r\n“90756”,,,\"Influenza virus vaccine, quadrivalent, antibiotic free, for intramuscular use\",,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0027", "char_start": 30042, "char_end": 31242, "pages": [12], "text": "e Procedure Description\n“90473” Immunization administration of seasonal influenza intranasal vaccine for ages 19\nand above $8.57\n“90471” Immunization administration (includes percutaneous, intradermal, subcutaneous,\nor intramuscular injections); one vaccine (single or combination vaccine/toxoid)\n$13.23\n“90472” Immunization administration (includes percutaneous, intradermal, subcutaneous,\nor intramuscular injections); each additional vaccine (single or combination\nvaccine/toxoid) (list separately in addition to code for primary procedure) $13.23\n“90460” Immunization administration of free vaccine through VFC Program for ages under\n19 years $17.85\nFor additional information on the procedure codes for vaccines found in the tables above, refer to the OTC\nand Supply Fee Schedule document on the eMedNY “Pharmacy Manual” web page at:\nhttps://www.emedny.org/ProviderManuals/Pharmacy/index.aspx.\nQuestions and Additional Information:\n• Medicaid FFS billing/claims questions should be directed to the eMedNY Call Center by phone at\n(800) 343-9000.\n• MMC enrollment, reimbursement, billing, and/or documentation requirement questions should be\ndirected to the MMC enrollee’s specific MMC Plan. Provi", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0028", "char_start": 31242, "char_end": 32348, "pages": [12], "text": "ders can access individual plan information\nvia the NYS “MMC Pharmacy Benefit Information Center” web page at:\nhttps://mmcdruginformation.nysdoh.suny.edu/, then select the individual plan and choose\n“Pharmacy Vaccine Billing Guidance”.\n• Additional information on influenza can be found on the NYS DOH “What You Should Know About the\nFlu” web site at: http://www.health.ny.gov/diseases/communicable/influenza/.\n• Additional vaccine and immunization information can be found on the CDC “Vaccine and\nImmunizations” web page at: http://www.cdc.gov/vaccines/.\n• Additional information on the pharmacy administration of immunizations can be found on the NYS\nEducation Department “Administration of Immunizations” web page at:\nhttp://www.op.nysed.gov/prof/pharm/pharmimmunizations.htm.\n• NYS Medicaid coverage policy and billing guidance for COVID-19 vaccine administration can be found\nwithin the NYS Medicaid Coverage Policy and Billing Guidance for the Administration of COVID-19\nVaccines Authorized for Emergency Use at:\nhttps://health.ny.gov/health_care/medicaid/covid19/guidance/docs/billing_guidance.pdf.\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0029", "char_start": 32459, "char_end": 33659, "pages": [12, 13], "text": "\nAugust 2021 New York State Medicaid Update pg. 12\n\nClarification and Reminder:\nPharmacy Providers Servicing Medicaid Fee-for-Service Members\nand Medicaid Managed Care Enrollees\nNew York State (NYS) Medicaid fee-for-service (FFS) and Medicaid Managed Care (MMC) require\nmember/enrollee consent prior to requesting a renewal or new prescription from a prescriber and before\nsubmitting a claim for a refill. The article titled Attention Pharmacy Providers: New Prescriptions, published in\nthe May 2021 issue of the Medicaid Update, located at: https://www.health.ny.gov/health\n_care/medicaid/program/update/2021/docs/mu_no06_may21_pr.pdf, directed pharmacies to document\nconsent for renewals and refills. This guidance is to clarify that most software systems and methods of\noutreach or intake (i.e., electronic) can capture the details of request and consent.\nPharmacies should not directly outreach to prescribers for renewals, or refill a prescription, without\na member/enrollee or member/enrollee designee’s request first. Additionally, pharmacies may not\nenroll their Medicaid FFS members or MMC enrollees in automatic refill programs.\nRenewals/New Prescriptions\nA NYS FFS member or MMC enrollee, ", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0063::table", "char_start": null, "char_end": null, "pages": [12], "text": ",Procedure Code,,,Procedure Description,\r\n“90473”,,,\"Immunization administration of seasonal influenza intranasal vaccine for ages 19\nand above $8.57\",,\r\n“90471”,,,\"Immunization administration (includes percutaneous, intradermal, subcutaneous,\nor intramuscular injections); one vaccine (single or combination vaccine/toxoid)\n$13.23\",,\r\n“90472”,,,\"Immunization administration (includes percutaneous, intradermal, subcutaneous,\nor intramuscular injections); each additional vaccine (single or combination\nvaccine/toxoid) (list separately in addition to code for primary procedure) $13.23\",,\r\n“90460”,,,\"Immunization administration of free vaccine through VFC Program for ages under\n19 years $17.85\",,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0030", "char_start": 33659, "char_end": 34859, "pages": [13], "text": "who has exhausted prescription refills, may obtain a renewal in one\nof the following three ways:\n1. The Medicaid member/enrollee may contact their prescriber for a renewal.\n2. The Medicaid member/enrollee may contact their pharmacy for a renewal and give the pharmacy\nconsent to contact the prescriber on their behalf.\n3. The pharmacy may contact the Medicaid member/enrollee to inquire if a renewal is necessary, obtain\nconsent if necessary, and then contact the prescriber on their behalf.\nReminders regarding original prescriptions:\n• A prescription/fiscal order must originate from the office of the prescriber.\n• A fax-back may not be used to bill a prescription/fiscal order to Medicaid.\n• A fax received as a failed electronic prescription order may not be used to bill a prescription/fiscal\norder to Medicaid.\n• A fax received at the pharmacy, that is not on an Official NYS Prescription (ONYSRX) form with its\nunique serial number, is not an original prescription.\nRefills\nA NYS FFS member or MMC enrollee may obtain a refill in one of the following two ways:\n1. The Medicaid member/enrollee may contact their pharmacy requesting a refill.\n2. The pharmacy may contact the Medicaid member/enr", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0031", "char_start": 34859, "char_end": 36059, "pages": [13, 14], "text": "ollee to inquire if a refill is necessary, obtain\nconsent if necessary, and then submit a claim for dispensing on their behalf.\nAugust 2021 New York State Medicaid Update pg. 13\n\nEarly Fill-Vacation\nNYS Medicaid ensures an ample supply of medication(s) to accommodate for most temporary absences and\nallows a 90-day supply for most maintenance medications. As explained in the article titled New Medicaid\nFFS Pharmacy Early Fill Edit in the January 2015 issue of the Medicaid Update, located at:\nhttps://www.health.ny.gov/health_care/medicaid/program/update/2015/jan15_mu.pdf, members/enrollees\nare allowed to fill before the total amount of previous supply was used. A claim will pay if more than a 75\npercent of the previously dispensed amount has been used, or up to a 10-day supply of medication is\nremaining of the cumulative amount that has been dispensed over the previous 90 days (the more stringent\nrule will apply). Member/enrollees can still refill their prescription(s) early, allowing for an ample supply of their\nmedication(s) on hand.\nMembers/enrollees must prepare well in advance of travel and have the following options to ensure they have\nthe supply needed for a temporary absence:", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0032", "char_start": 36059, "char_end": 37259, "pages": [14], "text": "\n• A member/enrollee may arrange with a pharmacy for:\na possible 90-day supply for certain maintenance medications (members/enrollees may ask\ntheir prescriber to increase the day supply dispensed when the member/enrollee has been\nstabilized on the medication and has been taking their medication on a consistent basis though\nit may require a new prescription) and/or\na possible early fill up to allow amounts outlined above.\n• A member/enrollee can make alternative arrangements, such as relying on a trusted friend or family\nmember, to have necessary medication mailed in a secure method that will guarantee delivery.\nPlease note: Early filling of more than the allowed amount for vacation or a temporary absence, as stated\nabove and in the above linked article, for either Medicaid FFS members or MMC enrollees, is not permissible.\nFor additional information regarding original prescriptions being required for renewals, refills, and early fill,\nproviders may refer to the eMedNY “Pharmacy Manual” web page at:\nhttps://www.emedny.org/ProviderManuals/Pharmacy/index.aspx.\nQuestions:\n• Questions regarding this policy should be directed to the Medicaid Pharmacy Policy Unit by phone at\n(518) 486-3209", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0033", "char_start": 37259, "char_end": 37401, "pages": [14], "text": " or by email at PPNO@health.ny.gov.\n• Questions regarding early fill cumulative amounts for MMC enrollees should be directed to the MMC\nPlan.\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0034", "char_start": 37512, "char_end": 38712, "pages": [14, 15], "text": "\nAugust 2021 New York State Medicaid Update pg. 14\n\nPolicy and Billing\nNew Billing Requirement for Home Health Agencies:\nDemand Billing, No-Pay RAP\nOn January 1, 2021, the Centers for Medicare and Medicaid Services (CMS) implemented a new Medicare\nbilling requirement for Home Health Agencies (HHAs) requiring a No-Pay Request for Anticipated Payment\n(RAP) for all dual-eligible Medicare/Medicaid recipients prior to billing each final claim. The No-Pay RAP must\nbe submitted within five calendar days after the start of care date for the first 30 day period of care in a 60\nday certification period and within five calendar days after the “from date” for the second 30 day period of\ncare in the 60 day certification period. This CMS billing requirement must be s‐atisfied for all dual-eligible‐\nMedicare/Medicaid recipients even if the final claim is not intended to be billed to Medic‐are. Effective\nimmediately, ‐all HHAs must submit No-Pay RAPs to Medicare for all services rendered to dual-eligible\nMedicare/Medicaid recipients.\nThe Office of the Medicaid Inspector General (OMIG) has contracted with the University of Massachusetts\nMedical School (UMass) to perform Home Health Medicare Maximiz", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0035", "char_start": 38712, "char_end": 39912, "pages": [15], "text": "ation Services. This contract seeks to\nmaximize Medicare reimbursement for dual-eligible Medicare/Medicaid recipients who have received home\nhealth care services paid by Medicaid. Under this OMIG project, HHAs may be directed to demand bill claims\nto Medicare to ensure Medicaid remains the payor of last resort.\nDemand Bill Directives will be issued in September 2021 to inform HHAs which claims require a Medicare\ndemand bill submission. The dates of service included in the upcoming review period overlap with the start of\nthe new CMS No-Pay RAP billing requirements. HHAs should have initiated a No-Pay RAP prior to receipt of\nthe Demand Bill Notice. If the No-Pay RAP was not submitted in compliance with the new Medicare billing\nrequirement for any period of care on the Demand Bill Directive, the HHA should take the following three\nsteps:\n1. submit a No-Pay RAP to CMS for all identified dates of service,\n2. file a Demand Bill final claim with a KX modifier and indicate within the Remarks section of the claim\n“late RAP due to Medicaid TPL demand billing request”, and\n3. follow all outlined instructions within the Demand Bill Directive pertaining to timely and complete\nsubmission of info", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0036", "char_start": 39912, "char_end": 40182, "pages": [15], "text": "rmation and documentation to UMass.\nCMS is allowing the above steps as a temporary fix for the submission of demand bills for which No-\nPay RAPs were not previously submitted.\nQuestions\nAll questions regarding this article should be directed to UMass at (866) 626-7594.\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0037", "char_start": 40293, "char_end": 41493, "pages": [15, 16], "text": "\nAugust 2021 New York State Medicaid Update pg. 15\n\nNew York State Medicaid Drug Testing Policy\nThe drug testing policy guidance in this article is effective September 1, 2021 for Medicaid fee-for-service\n(FFS) and effective October 1, 2021 for Medicaid Managed Care (MMC) Plans [including mainstream MMC\nPlans, HIV (Human Immunodeficiency Virus) Special Needs Plans (SNPs), as well as Health and Recovery\nPlans (HARPs)]. This article updates the New York State (NYS) Medicaid drug testing policy published in the\nApril 2017 issue of the Medicaid Update.\nNYS Medicaid drug testing policy follows a two-step testing process/structure that consists of the use of\nscreening (presumptive) tests then confirmatory (quantitative) tests. Presumptive drug class screening tests\nusing Common Procedural Terminology (CPT) codes “80305”, “80306” or “80307” are the first step in the\nprocess. Only substances that return positive results or are inconclusive on screening tests (presumptive) or\nresults on screening tests that are inconsistent with clinical presentations are reimbursable for confirmation\n(quantitative) testing using CPT codes “80321” through “80377” listed on the fee schedule. Definitive or\ndi", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0038", "char_start": 41493, "char_end": 42693, "pages": [16], "text": "rect confirmation tests using CPT code “G0480” are only reimbursable when no screening methods for the\nsubstances are available.\nTest(s) for a drug(s) or drug classes must be ordered by the provider and should be considered for inclusion\nbased on the patient’s medical history and/or current clinical presentation. Broad panel tests, reflex tests\ninitiated by the lab, and routine standing orders are not reimbursable. Medical records must support the need\nfor each drug or drug class being tested and must be kept on file, in accordance with regulations, for audit\npurposes.\nTable: Presumptive Drug Class Screening\nCPT Code Description\n“80305” Drug tests(s), presumptive, any number of drug classes; any number of devices or\nprocedures, (e.g., immunoassay) capable of being read by direct optical observation\nonly (e.g., dipsticks, cups, cards, cartridges), includes sample validation when\nperformed, per date of service.\n“80306” Drug test(s), presumptive, any number of drug classes, qualitative, any number of\ndevices or procedures, (e.g., immunoassay) read by instrument assisted direct optical\nobservation (e.g., dipsticks, cups, cards, cartridges), includes sample validation when\nperformed, pe", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0039", "char_start": 42693, "char_end": 43893, "pages": [16], "text": "r date of service.\n“80307” Drug test(s), presumptive, any number of drug classes, qualitative, any number of\ndevices or procedures by:\n• instrument chemistry analyzers (e.g., utilizing immunoassay [e.g., EIA, ELISA,\nEMIT, FPIA, IA, KIMS, RIA]),\n• chromatography (e.g., GC, HPLC), and\n• mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-\nMS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF)\nIncluding sample validation when performed, per date of service.\nNote: Test abbreviations are defined in order of citation in table as follows: EIA/ELISA – enzyme-linked immunosorbent assay; EMIT\n– enzyme multiplied immunoassay technology; FPIA – fluorescence polarization immunoassay; IA – immunosorbent assay; KIMS –\nKinetic Interaction of Microparticles in Solution; RIA – radioimmunoassay; GC – gas chromatography, HPLC – high performance\nliquid chromatography; DART – direct analysis in real time; DESI – desorption electrospray ionization; GC-MS – gas\nchromatography mass spectrometry; GS-MS/MS – gas chromatography (tandem) mass spectrometry; LC-MS – liquid\nchromatography mass spectrometry; LC-MS/MS – liquid chromatography (tandem) mass spectrometry; LDTD – laser diode therma", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0040", "char_start": 43893, "char_end": 45093, "pages": [16, 17], "text": "l\ndesorption; MALDI – matrix-assisted laser desorption/ionization; MALDI-TOF – time of flight.\nAugust 2021 New York State Medicaid Update pg. 16\n\nTesting of the following drug/drug classes are included in screening by NYS Medicaid:\n• Alcohol\n• Amphetamines\n• Barbiturates\n• Benzodiazepines\n• Buprenorphine\n• Clonazepam\n• Cocaine\n• Fentanyl\n• Kratom (Mitragyna speciosa; Mitragynine; 7-hydroxymitragynine)\n• Lorazepam\n• Methadone\n• Methadone metabolites\n• Opiates\n• Oxycodone\n• Phencyclidine\n• 6-monacetylmorphine (6-MAM)\n• Synthetic cannabinoids [5-fluoro-MDMB-PICA (methyl dimethylbutanoate – one pot procedure indole\n<gives> carbolic acid)] (K1 and K2: Group 1 and Group 2)\n• Tetrahyrdrocannabinol (THC) metabolites (marijuana)\n• Tramadol\nThe reimbursement for codes “80305”, “80306” and “80307” in the Table cover the screening tests of one\nspecimen for all drugs listed above. The codes should only be billed once irrespective of the number of drug\nclass procedures or results on any date of service. Screening by broad-spectrum chromatographic procedure,\nwhich detects multiple drug classes, should be billed using code “80307”. Each step in the sequential\ndevelopment of a chromatograph is not ", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0064::table", "char_start": null, "char_end": null, "pages": [16], "text": ",CPT Code,,,Description,\r\n“80305”,,,\"Drug tests(s), presumptive, any number of drug classes; any number of devices or\nprocedures, (e.g., immunoassay) capable of being read by direct optical observation\nonly (e.g., dipsticks, cups, cards, cartridges), includes sample validation when\nperformed, per date of service.\",,\r\n“80306”,,,\"Drug test(s), presumptive, any number of drug classes, qualitative, any number of\ndevices or procedures, (e.g., immunoassay) read by instrument assisted direct optical\nobservation (e.g., dipsticks, cups, cards, cartridges), includes sample validation when\nperformed, per date of service.\",,\r\n“80307”,,,\"Drug test(s), presumptive, any number of drug classes, qualitative, any number of\ndevices or procedures by:\n• instrument chemistry analyzers (e.g., utilizing immunoassay [e.g., EIA, ELISA,\nEMIT, FPIA, IA, KIMS, RIA]),\n• chromatography (e.g., GC, HPLC), and\n• mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-\nMS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF)\nIncluding sample validation when performed, per date of service.\",,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0041", "char_start": 45093, "char_end": 46293, "pages": [17], "text": "considered a separate procedure. Only when an analytical condition\n(e.g., column temperature or flow rate) is changed, such that additional controls must be run, is subsequent\nanalysis of the same specimen for additional drug(s) considered a separate procedure for billing purposes.\nScreening for drugs using immunoassay or enzyme assay using multichannel chemistry analyzers should be\nbilled using code “80307”. Use “80307” once to report single or multiple procedures performed, irrespective of\nthe number of procedures, classes, or results on any date of service.\nConfirmatory Drug Testing\nBilling for confirmatory testing using CPT Codes “80320” through “80377” is allowable when the codes are\nlisted on the fee schedule and one or more of the following conditions are met:\n• a presumptive positive drug screen is found using codes “80305”, “80306”, “80307” and/or\n• a screen result is inconclusive or inconsistent with clinical presentation\nFor confirmatory testing, providers should bill the appropriate code related to the drug/drug class. If there is no\nscreening method available for a drug class, providers can refer to “Definitive Drug Testing” below.\nAugust 2021 New York State Medicaid U", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0042", "char_start": 46293, "char_end": 47493, "pages": [17, 18], "text": "pdate pg. 17\n\nDefinitive Drug Testing\nDefinitive Testing (“G0480”) may be billed for testing of drugs or drug classes when there is no screening method\navailable. NYS Medicaid covers definitive drug testing using this code for up to seven drug classes. CPT code\n“G0480” is reimbursable once per date of service, up to a maximum of six times within 365 days. CPT code\n“G0480” cannot be billed in conjunction with CPT codes “80305”, “80306”, or “80307” for drugs/drug classes\nincluded in the screening codes (Table: Presumptive Drug Class Screening).\nCPT Code Description\n“G0480” Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and\ndistinguish between structural isomers (but not necessarily stereoisomers), including, but not\nlimited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and\nexcluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g.,\nalcohol dehydrogenase); qualitative or quantitative, all sources, includes specimen validity\ntesting, per day, 1-7 drug class(es), including metabolite(s) if performed.\nQuestions and Additional Information:\n• Medicaid FFS coverage and policy question", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0043", "char_start": 47493, "char_end": 48330, "pages": [18], "text": "s should be directed to the Office of Health Insurance\nPrograms (OHIP) Division of Program Development and Management (DPDM) by phone at (518) 473-\n2160 or by email at FFSMedicaidPolicy@health.ny.gov.\n• MMC general coverage questions should be directed to the OHIP Division of Health Plan Contracting\nand Oversight (DHPCO) at covques@health.ny.gov or (518) 473-1134.\n• MMC reimbursement and/or billing requirements questions should be directed to the enrollee’s MMC\nPlan. For an MMC directory by plan., providers can refer to the NYS Medicaid Program Information for\nAll Providers: Managed Care\nInformation document , located at at: https://www.emedny.org/ProviderManuals/AllProviders/PDFS/Info\nrmation_for_All_Providers_Managed_Care_Information.pdf.\n• FFS claim questions should be directed to the eMedNY Call Center at (800) 343-9000.\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0044", "char_start": 48441, "char_end": 49641, "pages": [18], "text": "\nNew York State Medicaid Expansion of Non-Invasive Prenatal\nTrisomy Screening Policy\nEffective September 1, 2021 for New York State (NYS) Medicaid fee-for-service (FFS) and effective\nNovember 1, 2021 for Medicaid Managed Care (MMC) Plans [including mainstream MMC Plans, HIV (Human\nImmunodeficiency Virus) Special Needs Plans (SNPs), as well as Health and Recovery Plans (HARPs)],\ncoverage of non-invasive prenatal trisomy screening using cell-free fetal DNA (deoxyribonucleic acid) will be\nexpanded to include pregnant members age 30 and older. Additionally, this coverage now includes twin\npregnancies, but not higher multi-gestational pregnancies. Consistent with current policy, non-invasive\nprenatal trisomy screening will continue to be covered when at least one of the following criteria is met:\n• either parent has a family history of aneuploidy in a 1st* or 2nd** degree relative;\n• standard serum screening or fetal ultrasonographic findings indicate an increased risk of aneuploidy;\n• parent(s) have a history of a previous pregnancy with a trisomy; and/or\n• either parent is known to have a Robertsonian translocation.\n*1st degree relatives: Parents, children, siblings\n**2nd degree relat", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0045", "char_start": 49641, "char_end": 50841, "pages": [18, 19], "text": "ives: Grandparents, aunts and uncles, nieces and nephews, and grandchildren\nNote: This is an update to the October 2014 Medicaid Update article titled NYS Medicaid Now Covers Non-\ninvasive Prenatal Testing for Trisomy 21, 18 and 13 which can be found at:\nhttps://www.health.ny.gov/health_care/medicaid/program/update/2014/oct14_mu.pdf.\nAugust 2021 New York State Medicaid Update pg. 18\n\nReminders:\n• Genetic counseling should be provided to women prior to non-invasive prenatal testing and to those\nwho test positive for a fetal chromosomal abnormality.\n• Prenatal testing of a fetus by amniocentesis or chorionic villus sampling will continue to be covered:\nsubsequent to a positive or high-risk score in a non-invasive prenatal trisomy screening test;\nor\nsubsequent to an inconclusive result in a high-risk pregnancy.\n• Diagnostic testing (e.g., cytogenetic analysis or molecular genetic testing) for suspected\naneuploidies continues to be covered if medically necessary.\n• Cell-free fetal DNA testing should not be offered to women who are pregnant with three or more\nfetuses because it has not been sufficiently evaluated in these groups.\n• Micro-deletion testing, in conjunction with non-invasiv", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0065::table", "char_start": null, "char_end": null, "pages": [18], "text": ",CPT Code,,,Description,\r\n“G0480”,,,\"Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and\ndistinguish between structural isomers (but not necessarily stereoisomers), including, but not\nlimited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and\nexcluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g.,\nalcohol dehydrogenase); qualitative or quantitative, all sources, includes specimen validity\ntesting, per day, 1-7 drug class(es), including metabolite(s) if performed.\",,\r\n", "chunk_type": "table", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0046", "char_start": 50841, "char_end": 52041, "pages": [19], "text": "e trisomy testing, is not reimbursable.\n• Consistent with existing policy, Title 18 of New York Consolidated Rules and Regulations (NYCRR)\n§505.7(g)(4) require that providers order tests individually. No payment will be made for tests ordered\nas groupings or combinations of tests. For more information on this and additional regulations\npertaining to laboratory services, refer to the “§505.7 - Laboratory Services” web page, located at:\nhttps://regs.health.ny.gov/content/section-5057-laboratory-services.\nQuestions and Additional Information:\n• Medicaid FFS coverage and policy questions should be directed to the Office of Health Insurance\nPrograms (OHIP) Division of Program Development and Management (DPDM) by phone at\n(518) 473−2160 or by email at FFSMedicaidPolicy@health.ny.gov.\n• MMC enrollment, reimbursement, billing and/or documentation requirement questions should be directed\nto the enrollee’s specific MMC Plan. Providers can refer to the NYS Medicaid Program Information for\nAll Providers: Managed Care Information document at: https://www.emedny.org/ProviderManuals/\nAllProviders/PDFS/Information_for_All_Providers_Managed_Care_Information.pdf, for an contact\ninformation per MMC P", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0047", "char_start": 52041, "char_end": 52149, "pages": [19], "text": "lan.\n• Medicaid FFS billing/claim questions should be directed to the eMedNY Call Center at (800) 343-9000.\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0048", "char_start": 52260, "char_end": 53460, "pages": [19, 20], "text": "\nAugust 2021 New York State Medicaid Update pg. 19\n\nMosquito Repellent Coverage Discontinued\nEffective September 1, 2021 for New York State (NYS) Medicaid fee-for-service (FFS) and Medicaid\nManaged Care (MMC) will cease coverage for mosquito repellent when prescribed to members/enrollees to\nprevent Zika virus infections. A previous article titled Mosquito Repellent Coverage, found in the September\n2016 issue of the Medicaid Update at: https://www.health.ny.gov/health_care\n/medicaid/program/update/2016/sep16_mu.pdf, indicated the coverage of mosquito repellent would continue\nuntil the risk of infection, as reported by the Centers for Disease Control and Prevention (CDC), reduced. The\nCDC reports there are no current Zika outbreaks worldwide and specifically, “There is no current local\ntransmission of the Zika virus in the continental United States (US)…”; therefore, NYS Medicaid will cease\ncoverage of mosquito repellant and will revisit this policy if the situation warrants. Exception requests will be\nhandled on a case-by-case basis.\nQuestions and Additional Information:\n• Questions regarding MMC enrollee exception requests and coverage should be directed to the\nindividual plan. Spe", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0049", "char_start": 53460, "char_end": 53864, "pages": [20], "text": "cific plan information can be found at the NYS MMC Pharmacy Benefit Information\nCenter web site at: https://mmcdruginformation.nysdoh.suny.edu/.\n• Additional information reported by the CDC can be found by visiting the following CDC web pages:\n“Zika Travel Information” web page at: https://wwwnc.cdc.gov/travel/page/zika-information\n“Zika in the US” web page at: https://www.cdc.gov/zika/geo/index.html\n", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0050", "char_start": 53975, "char_end": 55175, "pages": [20, 21], "text": "\nAugust 2021 New York State Medicaid Update pg. 20\n\nProvider Directory\nOffice of the Medicaid Inspector General:\nFor suspected fraud, waste or abuse complaints/allegations, call 1-877-87FRAUD, (877) 873-7283, or visit\nOffice of Medicaid Inspector General (OMIG) web site at: www.omig.ny.gov.\nProvider Manuals/Companion Guides, Enrollment Information/Forms/Training Schedules:\nPlease visit the eMedNY website at: www.emedny.org.\nProviders wishing to listen to the current week’s check/EFT amounts:\nPlease call (866) 307-5549 (available Thursday PM for one week for the current week's amount).\nFor questions about billing and performing MEVS transactions:\nPlease call the eMedNY Call Center at (800) 343-9000.\nProvider Training:\nPlease enroll online for a provider seminar at: https://www.emedny.org/training/index.aspx. For\nindividual training requests, call (800) 343-9000.\nBeneficiary Eligibility:\nCall the Touchtone Telephone Verification System at (800) 997-1111.\nMedicaid Prescriber Education Program:\nFor current information on best practices in pharmacotherapy, please visit the following web sites:\n• DOH Prescriber Education Program page:\nhttps://www.health.ny.gov/health_care/medicaid/progra", "chunk_type": "text", "category": "Medicaid Update"}
{"doc_id": "mu_no10_aug21_pr.pdf", "chunk_id": "mu_no10_aug21_pr.pdf::0051", "char_start": 55175, "char_end": 55974, "pages": [21], "text": "m/prescriber_education/presc-\neducationprog.\n• Prescriber Education Program in partnership with SUNY: http://nypep.nysdoh.suny.edu/.\neMedNY\nFor a number of services, including: change of address, updating an enrollment file due to an\nownership change, enrolling another NPI, or revalidating an existing enrollment, please visit the\neMedNY Provider Enrollment page at: https://www.emedny.org/info/ProviderEnrollment/index.aspx,\nand choose the appropriate link based on provider type.\nNY Medicaid Electronic Health Record (EHR) Incentive Program\nContact the New York Medicaid EHR Call Center at (877) 646-5410 for assistance.\nComments and Suggestions Regarding This Publication\nPlease contact the editor, Angela Lince, at medicaidupdate@health.ny.gov.\nAugust 2021 New York State Medicaid Update pg. 21", "chunk_type": "text", "category": "Medicaid Update"}
